No description
-
2002 (v1)PublicationUploaded on: December 5, 2022
-
2011 (v1)Publication
This clinical observation indicates that thyroid function needs to be monitored during therapy with natalizumab, as with other biological medicines, and that thyroid volume and antibody modulation are predictive factors of functional evolution during and after treatment.
Uploaded on: April 14, 2023 -
1996 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2000 (v1)Publication
No description
Uploaded on: December 2, 2022 -
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2004 (v1)Publication
BACKGROUND: Measurement of chromogranin A (CgA) levels in blood can be used to monitor neuroendocrine tumors (NETs). CgA levels may also be elevated in several other endocrine and non-endocrine diseases. It is well known that drugs affecting acid gastric secretion can increase gastrin. Proton-pump inhibitors are extensively used but only a...
Uploaded on: April 14, 2023 -
2005 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1998 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Background: The efficacy and safety of various modes of medical treatment for primary hyperparathyroidism in pregnancy are largely unknown. Case presentation: We report the case of a 34-year-old white woman with primary hyperparathyroidism symptomatic for nephrolithiasis. Her serum calcium was 3.15 mmol/l and parathyroid hormone was 109.0 ng/L....
Uploaded on: April 14, 2023 -
2005 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2004 (v1)Publication
No description
Uploaded on: March 31, 2023 -
1983 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2013 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2000 (v1)Publication
No description
Uploaded on: April 14, 2023 -
1997 (v1)Publication
No description
Uploaded on: December 5, 2022 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023